<DOC>
	<DOCNO>NCT01444482</DOCNO>
	<brief_summary>The safety parenterally administrate investigational vaccine ( commercial influenza vaccine formulate adjuvant Matrix M ) healthy adult ( age 18-50 ) healthy elderly ( age 65-75 ) , investigate study . Moreover , study aim study parameter associate improved protection clinical disease elderly . Such parameter include HI-titres , balance Th1/Th2 response well functional cellular immune response . Vaccination start 22 healthy adult receive investigational vaccine . Vaccination elderly initiate demonstration safety adult . 88 healthy elderly volunteer vaccinate , 44 receive seasonal influenza vaccine alone 44 receive investigational vaccine . Vaccines administrate intramuscularly upper arm . One dose administer volunteer include study . Blood sample basic immunological assessment cellular humoral immunity take day 0 , 7 , 28 , 90 150 . The investigational vaccine equal one standard human dose commercial seasonal influenza vaccine 50 µg adjuvant Matrix M add .</brief_summary>
	<brief_title>Study Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine Healthy Elderly Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Are age 18 50 year young adult part study Are age 65 75 year main study Have sign voluntary write informed consent . Volunteers cooperative , willing able participate adhere Protocol requirement Have minimum normal standard physical performance status Volunteer receive seasonal Influenza vaccine antigenic composition within 6 month prior enrolment Volunteer vaccine specific HI titres ≥ 40 Volunteer take immunosuppressant drug azathioprine , tacrolimus , cyclosporine , etc Volunteers primary secondary immunodeficiency ( e.g . Human Immunodeficiency Virus [ HIV ] ) Volunteers autoimmune disease Volunteer take oral , intramuscular intravenous corticosteroid . Use permit within 1 month Screening . Inhaled corticosteroid treat respiratory insufficiency ( e.g . chronic obstructive pulmonary disease [ COPD ] ) , permit Volunteer concurrent severe uncontrolled underlying medical disease unrelated likely compromise volunteer safety affect outcome study Volunteer neurotoxicity ( Grade ≥2 ) Volunteer diarrhoea ( Grade ≥2 ) Volunteer receive vaccine , within 1 month prior enrolment Volunteer history severe lifethreatening hypersensitivity reaction Volunteer unstable systemic disease ( include active infection , uncontrolled hypertension [ &gt; 160/100 ] , unstable angina , congestive heart failure , myocardial infarction within previous year , serious cardiac arrhythmia require medication , hepatic , renal metabolic disease ) Volunteer recent history ( within 6 month ) chronic alcohol drug abuse may compromise patient 's safety ability participate study activity Volunteer history psychiatric disorder prevents patient provide informed consent follow Protocol instruction Volunteer currently enrol investigational device drug trial , &lt; 1 month since complete investigational device drug trial Female volunteer pregnant lactating ( applicable PreStudy ) Volunteer factor opinion Investigator ( designee ) would make patient unsafe unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>